VST-1001 (Dilute Fluorescein) for Lymphatic Mapping & Localization of Lymph Nodes in Patients With Breast Cancer
Status:
Unknown status
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this Phase 1 portion of this clinical research study is to find out what dose
of dilute fluorescein is needed for a surgeon to best see important lymph nodes that need to
be removed during surgery (a standard of care surgery referred to as a Sentinel Lymph Node
Biopsy procedure) in patients diagnosed with breast cancer.
The purpose of the Phase 2 portion of this clinical research study is to find out if giving
dilute fluorescein sodium in combination with a radiotracer (a drug that is radioactive) can
help surgeons localize the lymph nodes that need to be removed in patients diagnosed by
breast cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Vestan, Inc.
Collaborators:
Huntsman Cancer Institute M.D. Anderson Cancer Center